![Rejuvenate Bio Secures $4M Funding from CIRM to Advance Breakthrough Gene Therapy for Rare Heart Condition](https://thetimesmag.com/wp-content/uploads/2024/07/Dan-Oliver-CEO-Co-Founder-of-Rejuvenate-Bio-500x400.jpg)
Rejuvenate Bio Secures $4M Funding from CIRM to Advance Breakthrough Gene Therapy for Rare Heart Condition
Rejuvenate Bio, a pioneering biotechnology firm specializing in gene therapies, announced today the reception of a $4 million grant from the California Institute for Regenerative Medicine (CIRM) to propel the development of its innovative gene therapy, RJB-0402, aimed at treating desmoplakin gene variant arrhythmogenic cardiomyopathy (DSP ACM). Desmoplakin gene variant arrhythmogenic cardiomyopathy (DSP ACM) is…